On June 11, the National Medical Products Administration (NMPA) website announced that Merck's clesrovimab‑cfor (Chinese trade name: Anfuchang) has been approved in China. It is indicated for the prevention of respiratory syncytial virus (RSV)‑related lower respiratory tract infections in neonates and infants who are entering or are born during their first RSV season.
Clesrovimab is a prophylactic, long‑acting monoclonal antibody designed to provide direct, rapid, and sustained protection throughout the RSV season (typically from autumn through the following spring) with a single 105 mg injection, regardless of body weight. In June 2025, clesrovimab was first approved in the United States, becoming the first and only RSV prevention option for infants that uses the same dose irrespective of weight.
In the Phase IIb/III trial MK‑1654‑004, preterm and full‑term infants (birth to 1 year) who received clesrovimab showed:
• Within 5 months post‑dose, the incidence of lower respiratory tract infection was reduced by 60.5% compared with placebo (0.026 vs 0.065, P<0.001).
• Within 5 months post‑dose, RSV‑related hospitalization rates were reduced by 84.3% versus placebo (0.004 vs 0.024, P<0.001).
In the Phase III trial MK‑1654‑007, infants receiving clesrovimab demonstrated:
• Within 5 months post‑dose, the incidence of lower respiratory tract infection was similar to that of palivizumab (3.6% vs 3.0%).
• Within 5 months post‑dose, RSV‑related hospitalization rates were comparable to palivizumab (1.3% vs 1.5%).